185 related articles for article (PubMed ID: 11669505)
1. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.
Albuquerque EX; Santos MD; Alkondon M; Pereira EF; Maelicke A
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S19-25. PubMed ID: 11669505
[TBL] [Abstract][Full Text] [Related]
2. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
Maelicke A
Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
[TBL] [Abstract][Full Text] [Related]
3. Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
Tariot PN
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S26-33. PubMed ID: 11669506
[TBL] [Abstract][Full Text] [Related]
4. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.
Coyle JT; Geerts H; Sorra K; Amatniek J
J Alzheimers Dis; 2007 Jul; 11(4):491-507. PubMed ID: 17656829
[TBL] [Abstract][Full Text] [Related]
5. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
Lilienfeld S
CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
[TBL] [Abstract][Full Text] [Related]
6. Nicotinic cholinergic modulation: galantamine as a prototype.
Woodruff-Pak DS; Lander C; Geerts H
CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
[TBL] [Abstract][Full Text] [Related]
7. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.
Coyle J; Kershaw P
Biol Psychiatry; 2001 Feb; 49(3):289-99. PubMed ID: 11230880
[TBL] [Abstract][Full Text] [Related]
8. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release.
Dajas-Bailador FA; Heimala K; Wonnacott S
Mol Pharmacol; 2003 Nov; 64(5):1217-26. PubMed ID: 14573772
[TBL] [Abstract][Full Text] [Related]
9. Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease.
Woodruff-Pak DS; Santos IS
Behav Brain Res; 2000 Aug; 113(1-2):11-9. PubMed ID: 10942028
[TBL] [Abstract][Full Text] [Related]
10. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats.
Potasiewicz A; Krawczyk M; Gzielo K; Popik P; Nikiforuk A
Behav Brain Res; 2020 May; 385():112547. PubMed ID: 32087183
[TBL] [Abstract][Full Text] [Related]
11. Galantamine: a review of its use in Alzheimer's disease.
Scott LJ; Goa KL
Drugs; 2000 Nov; 60(5):1095-122. PubMed ID: 11129124
[TBL] [Abstract][Full Text] [Related]
12. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.
Texidó L; Ros E; Martín-Satué M; López S; Aleu J; Marsal J; Solsona C
Br J Pharmacol; 2005 Jul; 145(5):672-8. PubMed ID: 15834443
[TBL] [Abstract][Full Text] [Related]
13. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR.
Samochocki M; Zerlin M; Jostock R; Groot Kormelink PJ; Luyten WH; Albuquerque EX; Maelicke A
Acta Neurol Scand Suppl; 2000; 176():68-73. PubMed ID: 11261808
[TBL] [Abstract][Full Text] [Related]
14. Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.
Ellis JR; Nathan PJ; Villemagne VL; Mulligan RS; Saunder T; Young K; Smith CL; Welch J; Woodward M; Wesnes KA; Savage G; Rowe CC
Psychopharmacology (Berl); 2009 Jan; 202(1-3):79-91. PubMed ID: 18949462
[TBL] [Abstract][Full Text] [Related]
15. Galantamine: additional benefits to patients with Alzheimer's disease.
Lilienfeld S; Parys W
Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():19-27. PubMed ID: 10971048
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
17. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.
Maelicke A; Samochocki M; Jostock R; Fehrenbacher A; Ludwig J; Albuquerque EX; Zerlin M
Biol Psychiatry; 2001 Feb; 49(3):279-88. PubMed ID: 11230879
[TBL] [Abstract][Full Text] [Related]
18. Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy.
Geerts H; Finkel L; Carr R; Spiros A
J Neural Transm Suppl; 2002; (62):203-16. PubMed ID: 12456064
[TBL] [Abstract][Full Text] [Related]
19. The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
Nikiforuk A; Potasiewicz A; Kos T; Popik P
Behav Brain Res; 2016 Oct; 313():214-218. PubMed ID: 27435422
[TBL] [Abstract][Full Text] [Related]
20. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
Bullock R; Erkinjuntti T; Lilienfeld S;
Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
